-
-
-
-
-
-
-
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
-
-
-
-
-
-
-
Fortress Biotech (FBIO) PT Raised to $13 at Roth/MKM
-
-
-
-
-
-
-
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
-
-
-
-
-
-
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
-
15,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

